图文详情
Patritumab deruxtecan (HER3-DXd), an antibody-drug conjugate (ADC), comprises a fully human anti-HER3 IgG1 monoclonal antibody, Patritumab, linked to a topoisomerase I inhibitor payload through a tetrapeptide-based cleavable linker, demonstrating anticancer activity [1].